Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Rhea-AI Summary

Biodesix (Nasdaq: BDSX) announced publication of the largest lung nodule biomarker validation: a retrospective pooled analysis of 1,100 patients with 4–30 mm noncalcified nodules. The Nodify CDT test showed high specificity of 91–97% across nodule sizes, four studies and 48 US clinical practices.

Results include data from the real-world CLARIFY study (NCT06728319) and support clinical use of Nodify CDT as a decision-support tool for earlier lung cancer diagnosis.

Positive

• Pooled cohort of 1,100 patients analyzed
• Specificity 91–97% across 4–30 mm nodules
• Consistent performance across four distinct studies
• Data from 48 US clinical practices included
• Includes real-world CLARIFY study (NCT06728319)

Negative

• Retrospective pooled analysis rather than prospective randomized study
• No sensitivity or clinical outcome (mortality) data reported

News Market Reaction – BDSX

-8.74%

4 alerts

-8.74% Session close to close

+6.5% Peak Tracked

-2.5% Trough Tracked

$148.07M Market Cap

0.5x Rel. Volume

In the Mar 20 session, BDSX declined 8.74%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.5% during that session. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -8.7% in the session following this news. A negative reaction despite supportive cli...

Analysis

The stock moved -8.7% in the session following this news. A negative reaction despite supportive clinical data would contrast with prior patterns where earnings and data updates, including the January preliminary results and February 2025 report, coincided with gains. The large 1,100‑patient study and 91–97% specificity strengthen Nodify CDT’s evidence base, but recent insider net selling and the stock’s advance from a $3.44 52‑week low could make the name more sensitive to profit‑taking.

Key Figures

Patients analyzed: 1,100 patients Nodule size range: 4–30 mm Specificity range: 91–97% +4 more

7 metrics

Patients analyzed 1,100 patients Retrospective pooled analysis for Nodify CDT validation

Nodule size range 4–30 mm Noncalcified lung nodules included in validation study

Specificity range 91–97% Nodify CDT test specificity across sizes and risk factors

Clinical studies pooled 4 cohort studies Retrospective pooled analysis sources

Clinical practices 48 clinical practices US practices contributing patients to the four studies

Malignant nodule progression over 40% Malignant pulmonary nodules that progressed in size before treatment

Nodule size eligibility 4–30 mm Lung nodules eligible for clinical use of Nodify CDT

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Earnings results	Positive	+7.8%	Reported strong Q4 and FY2025 results with first positive Adjusted EBITDA.
Feb 24	Investor conferences	Neutral	+2.0%	Announced participation in two March 2026 healthcare investor conferences.
Feb 12	Earnings date set	Neutral	+4.7%	Scheduled Q4 and full‑year 2025 earnings release and conference call.
Jan 12	Preliminary results	Positive	+48.0%	Issued upbeat preliminary Q4 and FY2025 revenue figures above prior guidance.
Dec 03	Scientific data	Positive	+4.0%	Outlined new Nodify Lung and ESR1 test data at upcoming scientific meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamental and data-related catalysts have tended to coincide with positive price reactions.

Recent Company History

Over the past few months, Biodesix has highlighted rapid growth and improving profitability, with Q4 2025 revenue of $28.8M and full‑year 2025 revenue of $88.5M, plus its first positive Adjusted EBITDA. Preliminary results on Jan 12, 2026 and final earnings on Feb 26, 2026 both drew strong positive reactions. Conference participation and new clinical data presentations in late 2025 also aligned with gains, providing a constructive backdrop for today’s large validation study on Nodify CDT.

Key Terms

autoantibody test, pulmonary nodules, noncalcified lung nodules, ct scan, +1 more

5 terms

autoantibody test medical

"Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30mm"

A blood or tissue assay that detects antibodies the immune system mistakenly makes against the body’s own cells or proteins, used to diagnose and monitor autoimmune conditions. For investors, results and demand for these tests signal clinical need, influence sales of diagnostics and related therapies, and can affect clinical trial enrollment and regulatory decisions—similar to a warning light that guides treatment choices and market opportunities.

pulmonary nodules medical

"risk in 4-30mm pulmonary nodules: a retrospective pooled analysis of four cohort"

Pulmonary nodules are small, round or oval spots found in the lungs on X-rays or CT scans; they can be scar tissue, infections, or early tumors. For investors, these findings matter because they can trigger diagnostic follow-up, treatment decisions, drug or device demand, clinical trial activity, regulatory scrutiny, and potential changes in healthcare costs or company valuations—think of a nodule like a small warning light that may or may not signal a serious engine problem.

noncalcified lung nodules medical

"Over 1,100 patients with noncalcified lung nodules ranging in size from 4-30 mm"

Noncalcified lung nodules are small soft spots seen on chest imaging that lack calcium deposits, meaning they are not hardened or scar-like. For investors, these findings matter because they can represent anything from harmless tissue to early-stage disease, influencing demand for diagnostic tests, treatments, clinical trials, insurance costs and regulatory decisions—think of them as ambiguous early warning signs that can change healthcare spending and company prospects.

ct scan medical

"whether to ‘watch and wait’ with imaging surveillance or, instead, to expedite intervention based on the limited insights provided by the CT scan"

A CT scan (computed tomography) is a medical imaging test that uses X‑rays and computer processing to create detailed cross‑sectional pictures of the body, like viewing thin slices of a loaf of bread to see inside. For investors, CT scans matter because they drive demand for imaging equipment, influence hospital and clinic revenue, affect diagnostic accuracy that guides treatment choices, and factor into reimbursement and regulatory decisions in the healthcare sector.

nct06728319 technical

"including the CLARIFY study (NCT06728319) where patients received the Nodify CDT test"

NCT06728319 is an identification code assigned to a specific clinical trial listed on ClinicalTrials.gov, the U.S. registry for medical studies. Think of it as a book’s library call number that lets investors and researchers quickly find the trial’s purpose, design, patient population, and reported results; knowing a trial’s status and outcomes helps investors assess the development progress, potential regulatory risks, and commercial prospects of related drugs or treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations

LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the clinical foundation for Nodify CDT® tests as a critical decision-support tool in the early detection of lung cancer, addressing a significant unmet need in the management of the millions of lung nodules detected annually in the United States. 

The study, published in Future Oncology, February 2026, titled Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30mm pulmonary nodules: a retrospective pooled analysis of four cohort studies, highlights that the Nodify CDT® test offers consistently strong performance in identifying a high risk of lung cancer in patients with lung nodules.

Over 1,100 patients with noncalcified lung nodules ranging in size from 4-30 mm and had Nodify CDT test results were analyzed. The data shows that the Nodify CDT test consistently demonstrated high specificity (91-97%), i.e., low false positive rates, regardless of nodule size or baseline patient risk factors. Test performance was also consistent across four distinct clinical studies with patients enrolled from 48 clinical practices in the US, including the CLARIFY study (NCT06728319) where patients received the Nodify CDT test as part of real-world clinical care. These data substantiate that the Nodify CDT test has strong clinical applicability and consistent performance across diverse practice settings.

“Most small nodules are benign and clinicians must balance patient care decisions … whether to ‘watch and wait’ with imaging surveillance or, instead, to expedite intervention based on the limited insights provided by the CT scan,”  said Dr. James Jett, Co-Chief Medical Officer at Biodesix, former Pulmonologist at Mayo Clinic, and Professor of Medicine Emeritus of National Jewish Health in Denver, CO.¹ Dr. Jett emphasized, “A recent study reported in the journal THORAX (by The SUMMIT consortium) observed that over 40% of malignant pulmonary nodules progressed in tumor size between the time of first detection and the time of definitive treatment.² This highlights a clinician’s need for more helpful decision-support tools to expedite diagnosis and treatment, such as Nodify Lung® Nodule Risk Assessment.”

“The data shows that the Nodify CDT test detected lung cancer with minimal false positives for nodules 4-30 mm in size,” confirmed Dr. Luke Yuhico, Pulmonologist, Fort Walton-Destin Hospital, FL.  “In my own practice, I have observed that using Nodify Lung testing, in conjunction with the information on the patient’s scan, significantly assists in my team’s decision-making as we strive to meaningfully impact patient outcomes by finding cancer much earlier, even in very small nodules.”

“This comprehensive validation study supports our continued commercial expansion of the Nodify CDT test and reinforces its clinical utility in addressing the substantial market opportunity and system-wide gaps in patient care that are presented by lung nodule management,” said Scott Hutton, CEO & President, Biodesix. “The demonstrated consistency of Nodify CDT tests, across real-world practice settings, further strengthens the company's offering with healthcare providers, payers, and clinical guideline committees.”

The Nodify CDT test is available for clinical use in patients with 4-30 mm lung nodules. To learn more about Nodify Lung testing, or to order a test for a patient, please visit www.biodesix.com.

Footnotes:
1.  Dr. James Jett, Co-Chief Medical Officer at Biodesix, is a board-certified physician in pulmonary medicine and served at the Mayo Clinic in Rochester, MN for 28 years. His is also Professor of Medicine Emeritus of National Jewish Health in Denver, CO.  He served as the Editor-in-Chief of the Journal of Thoracic Oncology and as Co-Editor of the Lung Cancer Section of the premier medical electronic textbook Up-To-Date.
2.  Upstaging of screen-detected lung cancers during diagnostic assessment, published as 10.1136/thorax-2025-224006, 2 Feb 2026, http://thorax.bmj.com/. Monica L Mullin, Priyam Verghese, Chuen R Khaw, Andrew Creamer, Amyn Bhamani, Ruth Prendecki, Jennifer L Dickson, Carolyn Horst, Sophie Tisi, Helen Hall, Kylie Gyertson, Esther Arthur-Darkwa, Laura Farrelly, John McCabe, Ricky Thakrar, Arjun Nair, Anand Devaraj, Neal Navani, Allan Hackshaw, The SUMMIT consortium, Sam M Janes.

About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843

FAQ

What did Biodesix (BDSX) announce about the Nodify CDT study on March 20, 2026?

They announced publication of the largest lung nodule biomarker validation, a retrospective pooled analysis of 1,100 patients. According to Biodesix, the study showed Nodify CDT specificity of 91–97% across 4–30 mm nodules and diverse practice settings.

How accurate is the Nodify CDT test for 4–30 mm lung nodules, per Biodesix (BDSX)?

The Nodify CDT test demonstrated high specificity of 91–97% for 4–30 mm nodules. According to Biodesix, this indicates consistently low false positive rates across nodule sizes and baseline risk factors.

Does the Biodesix (BDSX) study include real-world clinical data for Nodify CDT?

Yes. The pooled analysis includes patients from real-world settings, including the CLARIFY study (NCT06728319). According to Biodesix, data came from four studies spanning 48 US clinical practices.

Is the Nodify CDT test available for clinical use and which nodules qualify, per Biodesix (BDSX)?

The test is available for clinical use in patients with lung nodules sized 4–30 mm. According to Biodesix, clinicians can order Nodify Lung testing for decision support in that nodule size range.

What are limitations of the Biodesix (BDSX) Nodify CDT validation study investors should note?

The study is a retrospective pooled analysis rather than a prospective trial, which may limit causal inference. According to Biodesix, the published analysis focused on specificity and did not report sensitivity or clinical outcome endpoints.